Purpose: The classical taxanes (paclitaxel, docetaxel), the newer taxane
cabazitaxel and the nanoparticle-bound nab-paclitaxel are among the most
widely used anticancer drugs. Still, the optimal use and the value of
pharmacological personalization of the taxanes is still controversial.
Methods: We give an overview on the pharmacological properties of the
taxanes, including metabolism, pharmacokinetics-pharmacodynamic
relations and aspects in the clinical use of taxanes. The latter
includes the ongoing debate on the most effective and safe regimen, the
recommended initial dose, and pharmacological dosing individualization.
Conclusions: The taxanes are among the most widely used anticancer drugs
in patients with solid malignancies. Despite their longtime use in
clinical routine, the optimal dosing strategy (weekly versus 3-weekly)
or optimal average dose (cabazitaxel, nab-paclitaxel) has not been fully
resolved, as it may differ per tumor entity and line of treatment. The
value of pharmacological individualization of the taxanes (TDM, TCI) has
partly been explored for 3-weekly paclitaxel and docetaxel, but remains
mostly unexplored for cabazitaxel and nab-paclitaxel at present.